Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

Kiss, L. S. and Szamosi, Tamás and Molnár, P. and Miheller, Pál and Lakatos, L. and Vincze, Á. and Palatka, Károly and Barta, Zoltán and Gasztonyi, Beáta and Salamon, Ágnes and Horváth, Gábor and Tóth, G. T. and Farkas, K. and Banai, János and Tulassay, Z. and Nagy, F. and Szenes, Mária and Veres, Gábor and Lovász, B. D. and Végh, Z. and Golovics, Petra Anna and Szathmári, Miklós and Papp, M. and Lakatos, P. L. (2011) Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 34 (8). pp. 911-922. ISSN 0269-2813 (print), 1365-2036 (online)

Text APT11.34.pdf - Accepted Version Restricted to Registered users only Download (5MB) | Request a copy

Actions (login required)

Edit Item